Literature DB >> 12871047

An update on the extraneuronal monoamine transporter (EMT): characteristics, distribution and regulation.

F Martel1, I Azevedo.   

Abstract

Biological membranes prevent transmembrane diffusion in the majority of organic molecules that bear net charges at physiological pH. Consequently, these compounds must use more or less specific membrane-bound transport systems to be imported into or exported from cells or organisms. The extraneuronal monoamine transporter (EMT) is a transmembranar transport system involved in the transfer of monoamine compounds across cell membranes. It was identified more than 30 years ago [1], its functional characteristics being thereafter described [review by 2]. The recent cloning of this transporter in man and rat reopened investigation and interest in this entity. EMT is a Na(+) and Cl(-)-independent, potential-dependent carrier, known to have a broad tissue distribution (eg. myocardium, vascular and non-vascular smooth muscle cells, glandular cells, placenta and CNS glial cells). According to its transport function and primary structure, EMT is included in the amphiphilic solute facilitator (ASF) family of transporters. Physiological substrates for EMT include the monoamines serotonin, dopamine, noradrenaline, adrenaline and histamine. Moreover, several xenobiotics including the neurotoxin 1-methyl-4-phenylpyridinium, clonidine, cimetidine and the K(+)-channel blocker tetraethylammonium interact with this transporter. The aim of this work is to review knowledge concerning EMT, making an update on its functional characteristics, physiological importance and regulation. A special emphasis will be given to very recent investigations concerning regulation of EMT by intracellular second messenger systems and the interaction of modulators of P-glycoprotein, the product of the multidrug resistance gene MDR1, with EMT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871047     DOI: 10.2174/1389200033489433

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  6 in total

1.  Increased extracellular glutamate evoked by 1-methyl-4-phenylpyridinium [MPP(+)] in the rat striatum is not essential for dopaminergic neurotoxicity and is not derived from released glutathione.

Authors:  S B Foster; H Tang; K E Miller; G Dryhurst
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 2.  Neurotransmitter transporters and their impact on the development of psychopharmacology.

Authors:  Leslie Iversen
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

3.  Decreased anxiety in mice lacking the organic cation transporter 3.

Authors:  Thomas Wultsch; Gundula Grimberg; Angelika Schmitt; Evelin Painsipp; Heike Wetzstein; Alexandra Frauke Stephanie Breitenkamp; Dirk Gründemann; Edgar Schömig; Klaus-Peter Lesch; Manfred Gerlach; Andreas Reif
Journal:  J Neural Transm (Vienna)       Date:  2009-03-11       Impact factor: 3.575

4.  Enhanced norepinephrine output during long-term desipramine treatment: a possible role for the extraneuronal monoamine transporter (SLC22A3).

Authors:  John J Mooney; Jacqueline A Samson; John Hennen; Kathleen Pappalardo; Nancy McHale; Jonathan Alpert; Martha Koutsos; Joseph J Schildkraut
Journal:  J Psychiatr Res       Date:  2007-08-28       Impact factor: 4.791

5.  A serotonergic system in veins: serotonin transporter-independent uptake.

Authors:  A Elizabeth Linder; Wei Ni; Theodora Szasz; Robert Burnett; Jessica Diaz; Timothy J Geddes; Donald M Kuhn; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2008-03-05       Impact factor: 4.030

6.  Involvement of organic cation transporter-3 and plasma membrane monoamine transporter in serotonin uptake in human brain vascular smooth muscle cells.

Authors:  Rachel W S Li; Cui Yang; Y W Kwan; S W Chan; Simon M Y Lee; George P H Leung
Journal:  Front Pharmacol       Date:  2013-02-12       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.